UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Onyx Pharmaceuticals
In a report published Friday, Jefferies & Company reiterated its Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX), and raised its price target from $101.00 to $103.00.
Jefferies noted, “ONXX reported a strong Kyprolis U.S. sales launch w/ $19M in only 8 wks into the launch (v. JEF: $3M), citing contributing factors such as pre-identification of pts prior to launch, and Kyprolis as the first tx in the salvage setting serving an unmet medical need. As a result we have adjusted our 2012-2013 Kyprolis revenues and raised our PT to $103 from $101, and reiterate our Buy.”
Onyx Pharmaceuticals closed on Thursday at $80.33.
Latest Ratings for ONXX
|Nov 2013||Stifel Nicolaus||Terminates|
|Aug 2013||Maxim Group||Downgrades||Buy||Hold|
|Aug 2013||BMO Capital||Maintains||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.